Company facts
- Headquarters
- San Francisco, California
- Most recent report
- 8-K, filed Aug 11, 2026
- Filings on record
- 298 filings
- On EDGAR
- CIK 1974640
- Fiscal year ends
- December
- Filer status
- Large accelerated filer
Financials 8 of 13
News 8 of 39
Prospectuses and Registrations 8 of 16
- 424B5 Prospectus supplement for an offering Mar 25, 2026
- 424B5 Prospectus supplement for an offering Mar 23, 2026
- S-8 Registration statement for an employee plan Mar 2, 2026
- 424B5 Prospectus supplement for an offering Oct 10, 2025
- 424B5 Prospectus supplement for an offering Oct 8, 2025
- S-8 Registration statement for an employee plan Mar 3, 2025
- S-3ASR Automatic shelf registration Aug 12, 2024
- S-8 Registration statement for an employee plan Aug 12, 2024
Proxies 8 of 14
Ownership 8 of 191
- 4 Insider reported a trade Aug 11, 2026
- 4 Insider reported a trade Aug 7, 2026
- 4 Insider reported a trade Jul 24, 2026
- 4 Insider reported a trade Jul 16, 2026
- 4 Insider reported a trade Jul 10, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jul 8, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jul 8, 2026
- SCHEDULE 13G/A Large holder reported a passive stake, amended Jul 8, 2026
Other 8 of 25
- ARS Annual report sent to shareholders Apr 24, 2026
- ARS Annual report sent to shareholders Apr 29, 2025
- ARS Annual report sent to shareholders Apr 24, 2024
- EFFECT Notice that a registration became effective Mar 7, 2024
- S-1MEF Mar 7, 2024
- CORRESP Reply to SEC staff Mar 5, 2024
- CORRESP Reply to SEC staff Mar 5, 2024
- UPLOAD Comment letter from SEC staff Feb 29, 2024
Everything here comes from Apogee Therapeutics, Inc.'s own filings on SEC EDGAR. The filing list is rechecked every hour.